Stay updated with breaking news from Celularity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial...
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...
Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experience...
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction...
FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing...